Mental health charity takes action to "get people talking"
A mental health charity is set to host a series of workshops in Swindon next week.
Swindon & Gloucestershire Mind (S&G Mind) will be hosting the events as part of Time to Talk Day on Thursday, February 6.
The workshops aim to get people talking about mental health and contribute to "the nation's biggest mental health conversation", with thousands expected to take part across the country.
People are encouraged to sign up for each session in advance, which will be held at the charity's Swindon Hub in The Parade between 10am and 3pm.
There will be an interactive art session where attendees are invited to create a large collaborative college while talking through their thoughts.
This will be followed by a workshop on Mind's Five Ways to Wellbeing; Connect, Be Active, Take Notice, Give and Keep Learning.
The day's events will then conclude with a Positive Self-Talk Workshop which will focus on how to use self-affirmations and gratitude to improve your mindset.
Your Community, Your News Subscribe to Swindon Advertiser now for either 50% off for a year or 3 months for £3. Stay connected with all local happenings. #CommunityNews #SpecialOffer pic.twitter.com/cPkWIK9PKx
— Swindon Advertiser (@swindonadver) January 20, 2025
Hazel Howe, CEO of S&G Mind, said: "Time to Talk Day is a reminder of the power of open conversations about mental health.
"This Time to Talk Day, we're asking people to get comfortable talking about mental health. Starting these conversations isn't always easy but being able to share experiences is so crucial; one in four people will experience a mental health problem in their lifetime.
"Whether it's sharing our own experiences or simply listening, every conversation can make a difference.
"The more we look at different ways to address mental health problems in the community, the better life is for all of us."
Read More: Police praise domestic abuse victim's bravery after ex-partner jailed
The Swindon branch of the charity was established in 1990 and has been providing vital mental health support and services to those in need in the area ever since.
For more information on the event, go to timetotalkday.co.uk.
John (not his real name) realised how important it is to be open and talk about mental health issues and is hugely grateful for the support he received.
He said: "I'm extremely grateful for the exceptional care I received from S&G Mind.
"Their expertise and compassion were invaluable to my healing journey.
"They created a safe and supportive space where I could openly explore my emotions.
"Through their guidance, I've developed valuable coping mechanisms and gained a deeper understanding of myself.
"I'm incredibly grateful for the positive changes I've experienced thanks to their support.
"I feel more confident, resilient and equipped to navigate life's challenges."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Is Fidelity Select Portfolio Medical Technology and Devices (FSMEX) a Strong Mutual Fund Pick Right Now?
If you have been looking for Sector - Health funds, a place to start could be Fidelity Select Portfolio Medical Technology and Devices (FSMEX). FSMEX has a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance. Zacks categorizes FSMEX as Sector - Health, a segment packed with options. Sector - Health mutual funds offer investors a focus on the healthcare industry, one of the largest sectors in the American economy. These funds can include everything from pharmaceutical companies to medical device manufacturers and for-profit hospitals. Fidelity is responsible for FSMEX, and the company is based out of Boston, MA. Fidelity Select Portfolio Medical Technology and Devices made its debut in April of 1998, and since then, FSMEX has accumulated about $4.48 billion in assets, per the most up-to-date date available. The fund is currently managed by Edward Yoon who has been in charge of the fund since May of 2007. Investors naturally seek funds with strong performance. This fund has delivered a 5-year annualized total return of 5.12%, and it sits in the middle third among its category peers. If you're interested in shorter time frames, do not dismiss looking at the fund's 3 -year annualized total return of 3.37%, which places it in the bottom third during this time-frame. It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower. When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Over the past three years, FSMEX's standard deviation comes in at 18.22%, compared to the category average of 15.64%. Over the past 5 years, the standard deviation of the fund is 19.24% compared to the category average of 16.64%. This makes the fund more volatile than its peers over the past half-decade. Investors should note that the fund has a 5-year beta of 0.92, which means it is hypothetically less volatile than the market at large. Alpha is an additional metric to take into consideration, since it represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which in this case, is the S&P 500. With a negative alpha of -7.95, managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns. Costs are increasingly important for mutual fund investing, and particularly as competition heats up in this market. And all things being equal, a lower cost product will outperform its otherwise identical counterpart, so taking a closer look at these metrics is key for investors. In terms of fees, FSMEX is a no load fund. It has an expense ratio of 0.63% compared to the category average of 1.11%. Looking at the fund from a cost perspective, FSMEX is actually cheaper than its peers. While the minimum initial investment for the product is $0, investors should also note that there is no minimum for each subsequent investment. Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included. Overall, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively similar performance, average downside risk, and lower fees, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) looks like a great potential choice for investors right now. Your research on the Sector - Health segment doesn't have to stop here. You can check out all the great mutual fund tools we have to offer by going to to see the additional features we offer as well for additional information. For analysis of the rest of your portfolio, make sure to visit for our full suite of tools which will help you investigate all of your stocks and funds in one place. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Get Your Free (FSMEX): Fund Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
12 hours ago
- Yahoo
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006. Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors. Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 6, placing it in top 38%. The fund is sponsored by State Street Global Advisors. It has amassed assets over $4.92 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. XBI seeks to match the performance of the S&P Biotechnology Select Industry Index before fees and expenses. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the U.S. common stocks listed on the NYSE, AMEX, NASDAQ National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same. Annual operating expenses for this ETF are 0.35%, making it one of the least expensive products in the space. It has a 12-month trailing dividend yield of 0.16%. Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio. Looking at individual holdings, Exact Sciences Corp (EXAS) accounts for about 3.12% of total assets, followed by Alnylam Pharmaceuticals Inc (ALNY) and Neurocrine Biosciences Inc (NBIX). The top 10 holdings account for about 27.11% of total assets under management. So far this year, XBI has lost about -6.31%, and is down about -8.60% in the last one year (as of 06/12/2025). During this past 52-week period, the fund has traded between $69.80 and $104.18. The ETF has a beta of 0.86 and standard deviation of 30.70% for the trailing three-year period, making it a high risk choice in the space. With about 129 holdings, it effectively diversifies company-specific risk. SPDR S&P Biotech ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, XBI is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space. First Trust NYSE Arca Biotechnology ETF (FBT) tracks NYSE Arca Biotechnology Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. First Trust NYSE Arca Biotechnology ETF has $1.04 billion in assets, iShares Biotechnology ETF has $5.32 billion. FBT has an expense ratio of 0.56% and IBB charges 0.45%. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SPDR S&P Biotech ETF (XBI): ETF Research Reports Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report First Trust NYSE Arca Biotechnology ETF (FBT): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
Why UnitedHealth Stock Imploded Last Month
UnitedHealth Group continued its historic drop in May, losing 26.6% during the month. The health insurer is facing new allegations of fraud and misconduct. The company's CEO suddenly stepped down, citing only "personal reasons." 10 stocks we like better than UnitedHealth Group › Shares of UnitedHealth Group (NYSE: UNH) fell in May, finishing the month down 26.6%. The collapse came as the S&P 500 (SNPINDEX: ^GSPC) gained 5.5% and the Nasdaq Composite (NASDAQINDEX: ^IXIC) gained 7.9%. The troubled health insurance giant faced a series of damning reports and allegations of fraud and misconduct following the sudden departure of its CEO. In May, UnitedHealth's then-CEO, Andrew Witty, announced he was stepping down, citing "personal reasons." The sudden loss of its CEO sent shockwaves through the company and signaled to investors the depth and scale of UnitedHealth's ongoing issues. The resignation came at the same time that the company told investors it was suspending guidance for 2025 due to surging medical costs. UnitedHealth was already facing an investigation from the Department of Justice in a civil case, but in May, it was revealed that the DOJ's Health Care Fraud Unit is conducting a criminal investigation into the company for Medicare fraud. Although it was revealed last month, the company has apparently been under criminal investigation for a year. Just a week after the DOJ revelation, The Guardian reported that UnitedHealth has been making secret bonus payments to nursing homes in order to keep ailing residents out of hospitals and save money. The report also claims the company staffed nursing homes with its own medical teams who, at times, interfered in order to keep residents who needed hospital care from receiving it. One former UnitedHealth executive told The Guardian, "You gain profitability by denying care, and when profitability suffers for the shareholders, that's when people get crazy and do things that are not appropriate." Just a year after the company's CEO was murdered in New York City, the company is still on its heels, with problems mounting. As James Harlow, senior vice president at Novare Capital Management, put it, "It just doesn't seem like they have a plan." All of this has shaken investor confidence, leading in April and May to the most severe drop for an S&P 100 company since Netflix fell 54% in May 2022, according to Dow Jones Market Data. There are just too many issues facing UnitedHealth at the moment, with no clear picture of an imminent turnaround. This once-seemingly stable investment looks far from it at the moment, and I would stay away from the stock. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Netflix. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. Why UnitedHealth Stock Imploded Last Month was originally published by The Motley Fool Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
